Comparison of the short-term efficacy and safety of surgical operation of neoadjuvant sintilimab and camrelizumab, both in combination with chemotherapy in the treatment of resectable non-small cell lung cancer: a single-center retrospective cohort study.

ABSTRACT:

Background

In recent years, neoadjuvant immunotherapy combined with chemotherapy has shown enhanced therapeutic efficacy and favorable surgical safety profile in the treatment of resectable non-small cell lung cancer (NSCLC). Currently, there has been no academic research that directly compares the efficacy of two different immune checkpoint inhibitors (ICIs). This study aims to evaluate the differences of the short-term efficacy and surgery-related safety of two different ICIs (sintilimab and camrelizumab), in conjunction with chemotherapy and followed by radical surgical resection in patients diagnosed with resectable NSCLC.

Methods

This is a single-center retrospective cohort study involving patients. All patients diagnosed with NSCLC at Tangdu Hospital between June 2018

SUBMITTER: Yao X 

PROVIDER: S-EPMC12557632 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature